John M. Kirkwood, M.D., Clinical Team LeaderUniversity of Pittsburgh School of Medicine

[We are] engaged in the molecular and immunohistological analysis of melanoma, studying tissues from the institutional, national, and international trials.
Area of Research: Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer

Checkpoints immunotherapies that target the PD-1/PD-L1 pathway have been successful against several cancers. However, they don’t work for all patients, so Dr. Kirkwood, along withHassane M. Zarour, M.D., is evaluating an approach that may be able to complement PD-1 immunotherapy. Specifically, they’re characterizing the TIGIT receptor and analyzing how its activity influences immune cell activity and pro-tumor immunosuppression, as well as how targeting TIGIT might reverse this immunosuppression and enhance the effectiveness of traditional checkpoint immunotherapy approaches through various mechanisms.

Projects and Grants

Targeting multiple inhibitory receptors in cancer patients

University of Pittsburgh School of Medicine | Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma | 2015

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.